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Abstract
Bacterial infections such as febrile urinary tract infection (fUTI) may run a complicated course that is difﬁcult to foretell on clinical evaluation
only. Because the conventional biomarkers erythrocyte sedimentation rate (ESR), leucocyte count, C-reactive protein (CRP) and
procalcitonin (PCT) have a limited role in the prediction of a complicated course of disease, a new biomarker—plasma midregional
pro-adrenomedullin (MR-proADM)—was evaluated in patients with fUTI. We conducted a prospective multicentre cohort study including
consecutive patients with fUTI at 35 primary-care centres and eight emergency departments. Clinical and microbiological data were
collected and plasma biomarker levels were measured at presentation to the physician. Survival was assessed after 30 days. Of 494 fUTI
patients, median age was 67 (interquartile range 49–78) years, 40% were male; two-thirds of them had signiﬁcant co-existing medical
conditions. Median MR-proADM level was 1.42 (interquartile range 0.67–1.57) nM; signiﬁcantly elevated MR-proADM levels were
measured in patients with bacteraemia, those admitted to the intensive care unit, and in 30-day and 90-day non-survivors, compared with
patients without these characteristics. The diagnostic accuracy for predicting 30-day mortality in fUTI, reﬂected by the area--
under-the-curve of receiver operating characteristics were: MR-proADM 0.83 (95% CI 0.71–0.94), PCT 0.71 (95% CI 0.56–0.85); whereas
CRP, ESR and leucocyte count lacked diagnostic value in this respect. This study shows that MR-proADM assessed on ﬁrst contact predicts
a complicated course of disease and 30-day mortality in patients with fUTI and in this respect has a higher discriminating accuracy than the
currently available biomarkers ESR, CRP, PCT and leucocyte count.
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Introduction
Urinary tract infections (UTIs) are one of the most common
bacterial infections. Febrile UTI (fUTI), reﬂecting acute pyelo-
nephritis, prostatitis or urosepsis, is a potentially serious
infection with a mortality rate of about 0.3%, but in bacterae-
mic fUTI the mortality may be as high as 7.5–30% [1,2].
Moreover, bacteraemia in fUTI is associated with prolonged
hospitalization and a complicated course [3–5], and occurs in
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up to 30% of those admitted to hospital and in 15% of patients
treated at home [6]. Evaluation of clinical symptoms fails to
provide accurate guidance to the clinician on which patients
have bacteraemia or who may run a complicated course, and
which patients may be safely treated at home. At present,
there is a lack of robust inﬂammatory biomarkers that may
help to determine the severity of disease in fUTI [7,8]. A
promising new biomarker is midregional pro-adrenomedullin
(MR-proADM). Adrenomedullin (ADM) has been detected in a
variety of tissues including kidneys. It has immune modulating,
metabolic and bactericidal activities, and is involved in regu-
lation of complement activity [9–12]. Reliable plasma mea-
surement of ADM is challenging because of its half-life time of
22 min [13]. MR-proADM, the more stable mid-regional
fragment of adrenomedullin, has been identiﬁed in the plasma
of patients with septic shock [13–15].
The aim of the present study is to assess the prognostic value
of plasma MR-proADM in adult patients with fUTI with respect
to bacteraemia, need for hospital admission and a complicated
course, as compared with current available biomarkers like
blood leucocyte count, erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP) and procalcitonin (PCT).
Patients and Methods
We conducted a prospective observational multicentre cohort
study of patients presenting with a presumptive diagnosis of
fUTI from January 2004 until March 2011. Participating centres
were 35 primary-care centres and eight emergency depart-
ments (ED) in the Netherlands as described previously [6,8].
The local ethics committees approved the study and all
participants provided written informed consent. Over 7 years,
we established a cohort of 869 patients. From this database,
we randomly selected (every other patient, e.g. the ﬁrst, third,
ﬁfth, etc.) frozen plasma samples of 494 patients for measure-
ment of MR-proADM.
Inclusion criteria were age ≥18 years, fever (≥38.0°C) and/or
a history of fever or shaking chills within 24 h before
presentation, at least one symptom of UTI (dysuria, perineal
pain or ﬂank pain) and a positive nitrite dipstick test or
leucocyturia. Exclusion criteria were current treatment for
urolithiasis or hydronephrosis, pregnancy, haemodialysis or
peritoneal dialysis, history of kidney transplantation or presence
of polycystic kidney disease. Patients were only included once.
Procedures and deﬁnitions
Clinical data and laboratory values were collected within 24 h
of enrolment by standardized questionnaires and reviewing the
medical record. All patients were empirically treated with
antibiotics according to local and national policy. Blood
cultures and clean midstream-catch urine cultures were
obtained before starting antimicrobial therapy and analysed
using standard microbiological methods. Bacteraemia was
deﬁned as growth of any pathogen in the blood culture,
except coagulase-negative staphylococci.
Plasma EDTA blood samples were collected, centrifuged
and stored at 80°C within 2 h of patient enrolment.
MR-proADM and PCT levels were measured after completion
of all study enrolments, using a Time Resolved Ampliﬁed
Cryptate Emission technology assay (TRACE, Kryptor
Compact, MR-proADM sensitive and PCT sensitive; Thermo-
ﬁsher—Brahms AG; Henningsdorf, Germany). The median
concentration of MR-proADM in a cohort of healthy individ-
uals was 0.39 nM (97.5th centile: 0.55 nM) [16]. According to
the manufacturer’s recommendation we tested MR-proADM
levels for different cut-off values [16,17]. Results of PCT
measurement to predict bacteraemia have been described
previously [8]. Measurements of CRP, ESR and leucocyte
count were only performed at enrolment when indicated by
the attending physician. All eight participating EDs applied
similar techniques. CRP was measured using immunoturbidi-
metric assay, cut-off values varied from 6 to 10 mg/L. ESR was
measured using the Westergren method, cut-off values:
<20 mm/h for men and women aged ≤50 years, 30 mm/h
for women >50 years and 15 mm/h for men >50 years.
Leucocyte count was measured using ﬂow cytometry, cut-off
value: 10.0 9 109/L. Data on biomarkers available in our study
population were: CRP (n = 319), ESR (n = 158), leucocyte
count (n = 372) and PCT (n = 321).
Endpoints
MR-proADM values were evaluated for their predictive ability
of primary and secondary endpoints, in comparison to that of
the other biomarkers. The primary endpoint was 30-day
mortality. Secondary endpoints were presence of bacteraemia
at admission, need for hospital admission as estimated by the
Acute Pyelonephritis Severity Index score (APSI score), and
need for intensive care unit (ICU) admission. The APSI score is
a prediction rule allocating points to age, sex, nursing home
residency, comorbidities and vital signs at presentation (van
Nieuwkoop et al. 2009 Prospective validation of acute pyelo-
nephritis severity index to predict clinical outcome [abstract
982]. Program and abstracts of the 47th Annual Meeting
Infectious Diseases Society of America (Philadelphia). Arling-
ton, VA: Infectious Diseases Society of America) .
Statistical analysis
The histograms of biomarker values were skewed and
log-normalized before analysis. Descriptive analysis included
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 1048–1054
CMI Starre et al. Biomarkers in febrile UTI 1049
means with conﬁdence intervals or medians and ranges, as
appropriate. Univariate analysis was performed using analysis
of variance, Student’s t-test or where appropriate Mann–
Whitney U-test for continuous variables and chi-square tests
for categorical variables. Continuous variables were added into
the models as continuous variables (except for the APSI score)
and log-normalized if data were not normally distributed. The
APSI score was analysed as a binary variable, using a cut-off
value of 100 points, based on previous data (van Nieuwkoop
et al. 2009).
To assess the prognostic ability of MR-proADM compared
with PCT and other conventional biomarkers in predicting the
primary and secondary endpoints, area-under-the-curve (AUC)
of receiver operating characteristics (ROC) curves were
calculated. The main conclusion regarding the predictive ability
of MR-proADM was based on this analysis. For each biomarker
corresponding positive and negative predictive values and
likelihood ratios were calculated for standardized cut-off values
in predicting the primary endpoint. Kaplan–Meier survival
curves were generated to illustrate survival probability and
clinical outcome for different levels of MR-proADM. The log
rank test was used to test the difference between survival
curves. Survival analysis was performed on the whole cohort,
ROC-analysis and sensitivity analysis were performed on the
subset of patients with data on the concerning biomarkers
available. A p-value <0.05 was considered to indicate statistical
signiﬁcance. SPSS software (version 20.0; SPSS Inc., Chicago, IL,
USA) was used for statistical analysis.
Results
In total, 494 patients were randomly selected from our
existing database resource. There were no signiﬁcant differ-
ences between our study population and the remainder of the
database population, except for having a signiﬁcantly older
population (p 0.027) with signiﬁcantly more patients with
diabetes (25%; p <0.001) in the selected study group (data not
shown). Median age of our study population was 67 (inter-
quartile range (IQR) 49–78) years, 40% were male and 66%
had co-existing medical conditions. Of 376 patients included at
the ED, 329 (88%) were hospitalized. None of the patients
recruited in primary care were hospitalized (Table 1).
In the ED group, 30-day mortality was 3% (n = 12) versus
an absence of 30-day mortality in the primary-care group. A
total of 101 (22%) patients with blood cultures taken at
presentation (n = 463) presented with bacteraemia, with
signiﬁcantly more patients in the ED group (n = 90/347, 26%,
p <0.001). Nineteen (5%) of the ED patients were admitted to
the ICU, of these two died. (Table 2).
MR-proADM versus other biomarkers in predicting 30-day
mortality
To deﬁne the prognostic accuracy of different biomarkers
for predicting 30-day mortality, ROC analyses were per-
formed. The AUC for MR-proADM (n = 494) was 0.83 (95%
CI 0.71–0.94), leucocyte count (n = 372) 0.44 (95% CI 0.26–
0.62), ESR (n = 158) 0.60 (95% CI 0.43–0.78), CRP
(n = 319) 0.59 (95% CI 0.37–0.81) and PCT (n = 321) 0.71
(95% CI 0.56–0.85). Based on the constructed AUCs,
MR-proADM has a higher discriminating accuracy for
TABLE 1. Baseline characteristics of 494 patients presenting
with febrile urinary tract infection
Characteristic
Febrile UTI
patients (n = 494)
Age, median years (IQR) 67 (49–78)
Male sex 198 (40)
Antibiotic pretreatment 171 (35)
Comorbidity
Any 325 (66)
Diabetes mellitus 121 (25)
Malignancy 56 (11)
Heart failure 76 (15)
Cerebrovascular disease 73 (15)
Chronic obstructive pulmonary disease 77 (16)
Chronic renal insufﬁciency 54 (11)
Urological history
Urinary tract disordera 126 (26)
Indwelling urinary catheter 40 (8)
Recurrent UTIsb 158 (32)
Presentation
At emergency department 376 (76)
Shaking chills 290 (59)
Dysuriac 366 (74)
Flank pain 283 (57)
Fever duration at presentation, median hours (IQR) 32 (16–66)
Heart rate >90 beats/min 258 (52)
Systolic blood pressure, mean mmHg  SD 130  23
Diastolic blood pressure, mean mmHg  SD 72  14
UTI, urinary tract infection; IQR, interquartile range; SD, standard deviation.
Data presented as n (%) unless otherwise stated.
aAny anatomical or functional abnormality of the urinary tract except urinary
catheter and history of nephrolithiasis.
bDeﬁned as three or more UTIs in the past 12 months or two or more UTIs in the
past 6 months.
cNot recorded in patients with indwelling urinary catheter.
TABLE 2. Overview of primary and secondary endpoints in
494 patients with febrile urinary tract infection
Endpoint
Febrile UTI
patients (n = 494)
Bacteraemia at presentationa 101/463 (22)
Hospitalization duration (days), median (IQR) 4 (0–7)
ICU admission 19 (4)
APSI score >100b 77 (16)
Mortality
Day 3 2/492 (0.4)
Day 30 12/485 (3)
Day 90 19/474 (4)
IQR, interquartile range; ICU, intensive care unit; APSI, Acute Pyelonephritis
Severity Index.
Data are presented in n (%) unless otherwise stated.
aNo blood culture performed in 31 patients.
bPrediction rule allocating points to age, sex, nursing home residency, comorbid-
ities and vital signs at presentation; patients with APSI score <100 can be safely
treated at home without risk of readmission and mortality.
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predicting 30-day mortality compared with the other
conventional biomarkers.
The 97.5th centile cut-off value of normal provided by the
manufacturer is 0.55 nM but in our target group this cut-off
lacks speciﬁcity. Hence, the positive and negative predictive
values and likelihood ratios for different MR-proADM cut-off
values were calculated (Table 3). Our data indicate that a
plasma MR-proADM level of 1.00 nM was the optimal cut-off
value to stratify 30-day mortality in patients with fUTI. Using
this cut-off, we calculated a sensitivity of 91.7% with a
speciﬁcity of 48.0%; negative predictive value 99.6%; positive
predictive value 4.3%; positive likelihood ratio 1.8; negative
likelihood ratio 0.2 (Table 3).
Need for hospital admission
In the prediction of need for hospitalization, as based on an
APSI score >100 points, MR-proADM outperformed PCT
(n = 321 patients with both data available) given the AUC for
MR-proADM of 0.82 (95% CI 0.77–0.88) compared with 0.69
(95% CI 0.62–0.77) for PCT. For prediction of bacteraemia,
MR-proADM and PCT performed about equally
(MR-proADM: AUC 0.78 (95% CI 0.72–0.85) and PCT 0.81
(95% CI 0.75–0.87)). As the predictive values might have been
inﬂuenced by antibiotic (pre)treatment (in 35% of the patients),
analysis was also performed separately in those with and
without antibiotics on study enrolment (n = 113 versus
n = 208). Corresponding AUCs for MR-proADM were 0.75
(95% CI 0.65–0.85) and 0.79 (95% CI 0.70–0.88), and for PCT
were 0.80 (95% CI 0.71–0.89) and 0.80 (95% CI 0.72–0.88),
respectively, indicating that antibiotic pretreatment did not
alter the predictive value of MR-proADM with respect to
bacteraemia. In the prediction of either bacteraemia or need
for hospital admission, CRP, ESR and blood leucocyte counts
lacked predictive power (all AUC <0.60). For prediction of the
need for ICU admission, pro-ADM and PCT performed almost
identically (i.e. AUC of 0.77 and 0.75, respectively, n = 321).
MR-proADM and clinical parameters
In addition to 30-day mortality, median MR-proADM level was
signiﬁcantly correlated with bacteraemia (bacteraemic versus
non-bacteraemic patients: 1.60 (IQR 1.01–3.28) versus 0.96
(IQR 0.61–1.37) nM), need for ICU admission (ICU versus
non-ICU patients: 2.01 (IQR 1.37–4.61) vs. 1.04 (IQR 0.65–
1.50) nM) and APSI score (1.95 (IQR 1.27–2.90) nM in patients
with a score >100 points vs 0.94 (IQR 0.62–1.36) nM in
patients with a score ≤100 points). Furthermore, MR-proADM
levels increased with age and were signiﬁcantly higher in
patients with heart failure and chronic renal insufﬁciency.
The Kaplan–Meier curves showed no 30-day or 90-day
mortality in patients with MR-proADM levels in the ﬁrst quartile
(n = 123) of the whole group. In the second quartile (n = 124)
three events occurred, four in the third quartile (n = 124), and
eleven in the fourth quartile (n = 123). All three events in the
second quartile occurred late in the current disease episode:
days 16, 27 and 33. One event in the third quartile occurred on
day 3, the other three occurred late after disease onset (days 41,
42 and 66). Events in the fourth quartile occurred primarily in the
early stage of the current disease episode. This suggests that
events in the second and third quartile are probably due to
pre-existing co-morbidity, while events in the fourth quartile
occur as result of the current active disease (Fig. 1). The 30-day
cumulative survival rate was 1.00 in the ﬁrst quartile, 0.98 in the
second quartile (log rank p 0.157), 1.00 in the third quartile (log
rank p 1.00) and 0.92 in the fourth quartile (log rank p 0.001).
The 90-day cumulative survival rate was 1.00 in the ﬁrst quartile,
0.98 in the second quartile (log rank p 0.083), 0.97 in the third
quartile (log rank p 0.046) and 0.91 in the fourth quartile (log
rank p 0.001).
Discussion
The main ﬁnding of the present study is that MR-proADM,
determined on ﬁrst contact in a patient with presumptive fUTI,


















MR-proADM (nM) 0.55a 79 (16%) 100.0 (73.4–100.0) 15.6 (12.5–19.2) 2.9 (1.5–5.1) 100.0 (95.1–100.0) 1.2 (1.1–1.2) 0.0 (0.0–0.0)
1.00 234 (47%) 91.7 (61.5–98.6) 48.0 (43.4–52.6) 4.3 (2.2–7.5) 99.6 (97.6–99.9) 1.8 (1.5–2.1) 0.2 (0.0–1.1)
1.50 362 (73%) 83.3 (51.6–97.4) 74.6 (70.5–78.5) 7.7 (3.8–13.7) 99.4 (98.0–99.9) 3.3 (2.4–4.4) 0.2 (0.1–0.8)
1.88 406 (82%) 66.7 (35.0–89.9) 83.1 (79.4–86.4) 9.1 (4.0–17.1) 99.0 (97.4–99.7) 3.9 (2.5–6.2) 0.4 (0.2–0.9)
Procalcitonin (lg/mL) 0.25 129 (26%) 72.7 (39.1–93.7) 40.7 (35.1–46.3) 4.2 (1.8–8.1) 97.7 (93.3–99.5) 1.2 (0.8–1.8) 0.7 (0.3–1.8)
C-reactive protein (mg/L) 6 6 (1%) 100.0 (73.4–100.0) 1.3 (0.5–2.7) 2.5 (1.3–4.3) 100.0 (54.1–100.0) 1.0 (1.0–1.0) 0.0 (0.0–0.0)
8 10 (2%) 100.0 (73.4–100.0) 2.1 (1.0–3.9) 2.5 (1.3–4.3) 100.0 (69.0–100.0) 1.0 (1.0–1.0) 0.0 (0.0–0.0)
10 13 (3%) 100.0 (73.4–100.0) 2.8 (1.5–4.7) 2.5 (1.3–4.4) 100.0 (75.1–100.0) 1.0 (1.0–1.0) 0.0 (0.0–0.0)
ESR (mm) 20 74 (15%) 91.7 (61.5–98.6) 15.0 (11.9–18.6) 2.7 (1.3–4.7) 98.6 (92.5–99.8) 1.1 (0.9–1.3) 0.6 (0.1–3.7)
Leucocyte count (9109/L) 10 106 (22%) 75.0 (42.8–94.2) 21.8 (18.1–25.8) 2.4 (1.1–4.5) 97.2 (91.9–99.4) 1.0 (0.7–1.3) 1.2 (0.4–3.1)
MR-proADM, midregional pro-adrenomedullin; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio; ESR, erythrocyte sedimentation rate.
Data on biomarkers available: MR-proADM (n = 494), procalcitonin (n = 321), C-reactive protein (n = 319), ESR (n = 158), leucocyte count (n = 372).
a97.5th centile Brahms MR-pro-ADM Kryptor cut-off value in 144 healthy individuals.
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predicts a complicated course of disease necessitating hospital
admission and admission to the ICU, and a worse outcome of
infection as reﬂected by 30-day mortality. MR-proADM more
accurately predicts outcome than currently used biomarkers.
Furthermore, we found signiﬁcantly higher plasma
MR-proADM levels in patients presenting with bacteraemia.
Given these characteristics, measurement of MR-proADM in
patients with a presumptive diagnosis of fUTI may provide the
clinician with more accurate guidance than currently applied
biomarkers, e.g. with respect to admission of high-risk
patients, and so help to focus resources on the patients that
need them most.
Strengths of this study are its prospective design in which
fUTI patients were included in both primary care and hospital
ED settings, reﬂecting a real-life, full spectrum of invasive UTI
recognizable to every clinician. Also, the large sample size of a
clinically and microbiologically well-characterized disease
group is a strength. To our knowledge, this is the ﬁrst large
prospective study focusing on the predictive value of
MR-proADM in adult patients with fUTI, and making a
comparison to currently available biomarkers of inﬂammation
like PCT and CRP. Travaglino et al. showed that in febrile ED
patients, MR-proADM and PCT levels correlated with
APACHE-II score and the combined use of both biomarkers
might be helpful in predicting hospitalization [18].
There are also some limitations. We determined
MR-proADM levels once, at ﬁrst contact with the physician.
This precludes the analysis of whether a rise or decline in
MR-proADM levels correlates with changes in the clinical
course of disease, as has been determined, for example, for
PCT [19]. However, our ﬁndings show that having a single
baseline value can provide clinicians with guidance in predicting
a complicated clinical course at the ED or primary care. This is
where patients initially present and decisions have to be made
regarding treatment and hospital admission. When interpreting
MR-proADM, it should be taken into account that certain
patient characteristics like age and heart failure may affect the
plasma level of MR-proADM, as well as disease duration before
presentation. A technical limitation might be that the mea-
surement of MR-proADM and other biomarkers was per-
formed afterwards, and not immediately ‘at the bedside’.
However, it has been shown that frozen storage and
consequent freeze–thaw cycles of blood samples has no
inﬂuence on the analyte and measured concentration [15,20].
Finally, it should be realized that our ﬁndings pertain to fUTI
and need to be conﬁrmed in other infectious conditions. Of
note, similar ﬁndings have been made in other infectious states
albeit usually in much smaller groups of patients and rarely
prospectively [14,21–24].
We hypothesize that at least two mechanisms might be
responsible for the marked increase of MR-proADM in fUTI. In
vitro and in vivo studies have shown that the onset of
inﬂammation is accompanied by changes in both ADM and
pro-inﬂammatory cytokines, such as tumour necrosis factor-a
and interleukin-1. Plasma ADM levels are markedly increased
in patients with septic shock, supporting the hypothesis that
pro-inﬂammatory cytokines augment ADM production and
may increase plasma levels of ADM [11,25–27]. However,
ADM is also capable of upregulation of interleukin-6 in
non-stimulated and lipopolysaccharide-stimulated macrophag-
es, thereby suppressing LPS-induced tumour necrosis factor-a
production [28]. This suggests that ADM acts as part of a
regulatory loop balancing pro-inﬂammatory cytokines with its
anti-inﬂammatory actions. As LPS and cytokine levels were not
measured in our study, we cannot refute or conﬁrm this
hypothesis. Second, a decreased clearance of ADM by the
kidneys may be, at least in part, responsible for increased
proADM levels in fUTI. This is supported by our data with a
higher median MR-proADM in patients with chronic renal
insufﬁciency and studies that have shown a signiﬁcant corre-
lation between MR-proADM and creatinine levels [14,29].
In conclusion, we show that MR-proADM has a strong
predictive value for 30-day mortality in patients with fUTI
compared with more conventional biomarkers. Next, studies
may wish to conﬁrm the selected cut-off value as a predictor of
complicated course and evaluate using daily follow-up measure-
ments of MR-proADM the relationship to treatment and clinical
recovery. Such studies will establish whether MR-proADM
could function as a new prognostic tool for guidance in risk
stratiﬁcation and clinical outcome in patients with fUTI.
FIG. 1. Kaplan–Meier curves of 90-day mortality according to
quartiles of mid-regional pro-adrenomedullin (MR-proADM).
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